Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
- Status
- UNKNOWN
- Phase
- PHASE2
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
- Status
- COMPLETED
- Phase
- PHASE2
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Ph II CHOP+Velcade in Mediastinal LBCL
- Status
- TERMINATED
- Phase
- PHASE2